

Active substances set

Search phrase: abiraterone

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant prostate cancer

Abiraterone

Abiraterone is indicated with prednisone or prednisolone for: - the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) - the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated - the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO